ReviewChinese journal of cancer2014
Molecular biology of high-grade gliomas: what should the clinician know?
Review in Chinese journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Expression and Prognostic Significance of p53 in Glioma Patients: A Meta-analysis.Neurochemical research · 2016Pooled it
- Exosomes in Glioma: Diagnostic and Therapeutic Potentials.Advances in oncology · 2025Article
- Molecular classification and stratification of adult diffuse gliomas: A tertiary care center study.Journal of carcinogenesis · 2021Article
- The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients' Diagnosis and Prognosis.Brain sciences · 2020Article
- Clinicopathological Features and Prognosis of Indonesian Patients with Gliomas with IDH Mutation: Insights into Its Significance in a Southeast Asian Population.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Calycosin down-regulates c-Met to suppress development of glioblastomas.Journal of biosciences · 2019Article
- Multi-Label Nonlinear Matrix Completion With Transductive Multi-Task Feature Selection for Joint MGMT and IDH1 Status Prediction of Patient With High-Grade Gliomas.IEEE transactions on medical imaging · 2018Article
- Downregulation of long noncoding RNA PVT1 attenuates paclitaxel resistance in glioma cells.Cancer biomarkers : section A of Disease markers · 2018Article
- Progressive multifocal exophytic pontine glioblastoma: a case report with literature review.Chinese journal of cancer · 2017Review
- Pediatric spinal glioblastoma of the conus medullaris: a case report of long survival.Chinese journal of cancer · 2016Article
- Article
- Secreted and O-GlcNAcylated MIF binds to the human EGF receptor and inhibits its activation.Nature cell biology · 2015Article
- Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification.Annals of translational medicine · 2015Review
- The future of high-grade glioma: Where we are and where are we going.Surgical neurology international · 2015Article
- MIR-491: CDKN2A tumor suppressor co-pilot.Oncoscience · 2015Article
- Clinical management of grade III oligodendroglioma.Cancer management and research · 2015Review
- Heavy metals and epigenetic alterations in brain tumors.Current genomics · 2014Article
- High-grade gliomas: reality and hopes.Chinese journal of cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current World Health Organization classification system of primary brain tumors is solely based on morphologic criteria. However, there is accumulating evidence that tumors with similar histology have distinct molecular signatures that significantly impact treatment response and survival. Recent practice-changing clinical trials have defined a role for routine assessment of O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients, especially in the elderly, and 1p and 19q codeletions in patients with anaplastic glial tumors. Recently discovered molecular alterations including mutations in IDH-1/2, epidermal growth factor receptor (EGFR), and BRAF also have the potential to become targets for future drug development. This article aims to summarize current knowledge on the molecular biology of high-grade gliomas relevant to daily practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.